Glucagon-like peptide-1 (GLP-1) is a gut incretin hormone with cardioprotective effects. Human stem cells secreting a GLP-1 fusion protein and encapsulated in an alginate matrix (GLP-1 CellBeads) have been developed as a novel therapeutic agent. This study investigated the effects of GLP-1 CellBeads on post-myocardial infarction (MI) healing in a porcine model. GLP-1 CellBeads were delivered to the left anterior descending coronary artery to create micro-infarcts, with cell-free beads as controls. Hearts were explanted at 1 and 4 weeks post-MI. Gross infarct size was measured as a percentage of left ventricular area. Tissue was analysed for inflammation (number of MAC 387 positive cells/mm2), apoptosis (% TUNEL positive cells) and collagen (% picrosirius red staining).
Compared with controls (n=4), the GLP-1-treated group (n=6) exhibited less infarct at one (6.21%±0.64 vs 9.78%±1.80% 2LV, p=NS) and 4 weeks post-MI (4.7%±2.1 vs 21.8%±4.8% LV, p=0.02). Within the infarct there was increased inflammation in GLP-1-treated groups at both time points (1 week: 97.22%±19.62 vs 36.67%±7.78, p=0.01; 4 weeks: 24.2%±4.57 vs 12.3%±3.16, p=0.03). At 1 week, apoptosis rates in the infarct area were similar in both groups (1.46 %±0.57 vs 1.47 %±0.17, p=NS), with less apoptosis in the GLP-1-treated group at 4 weeks (0.51%±0.18 vs 1.84%±0.62, p=NS). Collagen content at 1 week was lower (5.14%±1.19 vs 9.95%±1.42, p=0.05) and at 4 weeks higher in the treated group (20.89%±8.25 vs 6.87%±2.92, p=NS). GLP-1 CellBeads have an effect on post-MI infarct size, inflammation and ventricular remodelling. These findings require further validation before clinical translation.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.